Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -177.24% is 19% above its 5-year average of -220.12%, near the high end of its 5-year range (-963.28%–-21.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.31% below its 12-month average of -171.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -177.24%.
RETURN ON EQUITY (ROE)
-177.24%
RETURN ON EQUITY (ROE) AVG TTM
-171.56%
RETURN ON EQUITY (ROE) AVG 3Y
-302.01%
RETURN ON EQUITY (ROE) AVG 5Y
-220.12%
RETURN ON EQUITY (ROE) AVG 10Y
-69.52%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.31%
CURRENT VS 3Y AVG
+41.31%
CURRENT VS 5Y AVG
+19.48%
CURRENT VS 10Y AVG
-154.95%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-321.91%
vs the sector median at left
Travere Therapeutics, Inc.
Market Cap
$5.19B
Return on Equity (ROE)
-177.24%
TTM Avg
-171.56%
3Y Avg
-302.01%
5Y Avg
-220.12%
Market Cap
$5.20B
Return on Equity (ROE)
24.56%
TTM Avg
11.91%
3Y Avg
-7.82%
5Y Avg
-3.31%
Market Cap
$5.22B
Return on Equity (ROE)
-25.83%
TTM Avg
-24.61%
3Y Avg
-23.01%
5Y Avg
-16.21%
Market Cap
$5.14B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$5.14B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
Market Cap
$5.26B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.05B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$5.33B
Return on Equity (ROE)
N/A
TTM Avg
-149.71%
3Y Avg
-15.45%
5Y Avg
-6097.55%
Market Cap
$5.00B
Return on Equity (ROE)
3.38%
TTM Avg
1.14%
3Y Avg
-0.67%
5Y Avg
-0.98%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | $5.19B | -177.24% | -171.56% | -302.01% | -220.12% |
| Sotera Health Company (SHC)vs › | $5.20B | 24.56% | 11.91% | -7.82% | -3.31% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.22B | -25.83% | -24.61% | -23.01% | -16.21% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.14B | -161.00% | -110.38% | -86.51% | -75.97% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.14B | -70.85% | -75.76% | -70.25% | -57.77% |
| Doximity, Inc. (DOCS)vs › | $5.26B | 18.24% | 20.62% | 17.32% | 27.02% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.05B | 8.67% | 8.42% | 7.80% | 5.80% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.33B | N/A | -149.71% | -15.45% | -6097.55% |
| Waystar Holding Corp. (WAY)vs › | $5.00B | 3.38% | 1.14% | -0.67% | -0.98% |
| Erasca, Inc. (ERAS)vs › | $4.95B | -79.37% | -38.23% | -43.73% | -49.41% |
ROE
-177.2%
ROA
-5.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -177.24% |
| 2026-03-31 | -21.70% |
| 2025-12-31 | -22.25% |
| 2025-09-30 | -120.36% |
| 2025-06-30 | -516.25% |
| 2025-03-31 | -690.70% |
| 2024-12-31 | -544.28% |
| 2024-06-30 | -963.28% |
| 2024-03-31 | -217.53% |
| 2023-12-31 | -55.47% |
| 2023-09-30 | -31.11% |
| 2023-06-30 | -263.93% |
| 2023-03-31 | -152.71% |
| 2022-12-31 | -649.88% |
| 2022-09-30 | -262.46% |
| 2022-06-30 | -146.90% |
| 2022-03-31 | -97.14% |
| 2021-12-31 | -59.61% |
| 2021-09-30 | -81.38% |
| 2021-06-30 | -71.34% |
| 2021-03-31 | -61.79% |
| 2020-12-31 | -80.22% |
| 2020-09-30 | -25.90% |
| 2020-06-30 | -28.88% |
| 2020-03-31 | -46.35% |
| 2019-12-31 | -66.20% |
| 2019-09-30 | -50.26% |
| 2019-06-30 | -51.12% |
| 2019-03-31 | -43.85% |
| 2018-12-31 | -32.26% |
| 2018-09-30 | -35.37% |
| 2018-06-30 | -26.43% |
| 2018-03-31 | -22.38% |
| 2017-12-31 | -20.38% |
| 2017-09-30 | -16.65% |
| 2017-06-30 | -23.67% |
| 2017-03-31 | -23.33% |
| 2016-12-31 | -15.56% |
| 2016-09-30 | -13.58% |
| 2016-06-30 | 32.10% |
| 2016-03-31 | 27.82% |
| 2015-12-31 | 39.08% |
| 2015-09-30 | 31.09% |
| 2015-06-30 | -22.99% |
| 2015-03-31 | -0.39% |
